AZ’ Lynparza shows similar QoL to placebo
AstraZeneca has presented late-stage data showing that patients taking its ovarian cancer therapy Lynparza not only benefitted from improved progression-free survival but also reported similar quality of life to those taking a placebo.
Read More
